Literature DB >> 30824607

Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody-Drug Conjugate Via Fc-FcγR Interaction.

Fu Li1, Michelle L Ulrich2, Vincent Feng-Sheng Shih3, Julia H Cochran2, Joshua H Hunter2, Lori Westendorf2, Jason Neale3, Dennis R Benjamin2.   

Abstract

To provide a better understanding of the pharmacokinetics-pharmacodynamics relationships of antibody-based drugs, we analyzed several chimeric and humanized monoclonal antibodies or antibody-drug conjugates (ADC) for PK and efficacy among four strains of mice. Notably, antibodies and ADCs displayed a dose-dependent drug disposition profile in the plasma of NSG mice. The increased clearance rate in NSG mice resulted in the reduction of antitumor activity of ADCs. Furthermore, we identified that the abnormal clearance was mediated by Fc-FcγR interaction by comparing antibodies that lack FcγR binding capacity. We also found a high percentage of FcγR-expressing macrophages in the bone marrow, spleen, and liver of NSG mice, which may be responsible for the abnormal distribution of antibodies. Overall, these findings suggest that preclinical evaluation of efficacy and pharmacokinetics of antibodies and ADCs need to consider mouse strain-induced variations. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30824607     DOI: 10.1158/1535-7163.MCT-18-0977

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  12 in total

1.  Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.

Authors:  Luke Jones; Hannah McCalmont; Kathryn Evans; Chelsea Mayoh; Raushan T Kurmasheva; Catherine A Billups; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Pediatr Blood Cancer       Date:  2019-04-23       Impact factor: 3.167

2.  Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations.

Authors:  Hsuan-Ping Chang; Se Jin Kim; Dhaval K Shah
Journal:  J Pharm Sci       Date:  2020-06-02       Impact factor: 3.534

3.  In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification.

Authors:  Jinghang Xie; Meghan A Rice; Zixin Chen; Yunfeng Cheng; En-Chi Hsu; Min Chen; Guosheng Song; Liyang Cui; Kaixiang Zhou; Jessa B Castillo; Chiyuan A Zhang; Bin Shen; Frederick T Chin; Christian A Kunder; James D Brooks; Tanya Stoyanova; Jianghong Rao
Journal:  Cancer Res       Date:  2021-02-26       Impact factor: 13.312

4.  FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion.

Authors:  Robert J Oldham; C Ian Mockridge; Sonya James; Patrick J Duriez; H T Claude Chan; Kerry L Cox; Vicentiu A Pitic; Martin J Glennie; Mark S Cragg
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

5.  Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.

Authors:  Yoshinobu Koguchi; Noriko Iwamoto; Takashi Shimada; Shu-Ching Chang; John Cha; Brendan D Curti; Walter J Urba; Brian D Piening; William L Redmond
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

Review 6.  In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies.

Authors:  Ami Patel; Mamadou A Bah; David B Weiner
Journal:  BioDrugs       Date:  2020-06       Impact factor: 5.807

7.  Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1.

Authors:  Junpeng Qi; David Hymel; Christopher G Nelson; Terrence R Burke; Christoph Rader
Journal:  Front Immunol       Date:  2019-08-21       Impact factor: 7.561

8.  The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of 89Zr-DFO-Pertuzumab.

Authors:  Delphine Vivier; Kimberly Fung; Cindy Rodriguez; Pierre Adumeau; Gary A Ulaner; Jason S Lewis; Sai Kiran Sharma; Brian M Zeglis
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

9.  Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse.

Authors:  Ikumi Katano; Ryoji Ito; Kenji Kawai; Takeshi Takahashi
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

10.  Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM.

Authors:  Sai Kiran Sharma; Maya Suzuki; Hong Xu; Joshua A Korsen; Zachary Samuels; Hongfen Guo; Brandon Nemieboka; Alessandra Piersigilli; Kimberly J Edwards; Nai-Kong V Cheung; Jason S Lewis
Journal:  J Nucl Med       Date:  2021-08-05       Impact factor: 11.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.